

Specialty drugs requiring precertification

All listed brands and their generic equivalents or biosimilars require precertification. This list is subject to change.

Alzheimer's disease agents

- Aduhelm™
- donanemab*
- Leqembi®

Amiotrophic lateral sclerosis agents

- NurOwn®

Antineoplastic agents

- Abraxane®
- Adcetris®
- Adstiladrin®
- AlymSYS® §
- Avastin® † §
- Anktiva®
- Avzivi®
- Azedra® †
- Blincyto®
- Columvi®
- Cyramza®
- Darzalex®
- Darzalex Faspro™
- Elahere™
- Enhertu
- epcoritamab*
- Epkinly®
- Erbitux®
- Erwinaze®
- glofitamab*
- Herceptin® †
- Herceptin Hylecta™
- Herzuma®
- Imjudo®
- Kadcyca®
- Kimmtrak®
- Kyprolis®
- Lunsumio™
- Margenza™
- Monjuvi®
- nogapendekin alfa inbakicept*
- Ogivri™
- Ontruzant®
- Opdualag™
- Padcev™

- patritumab
- deruxtecan*
- Pemfexy™
- Perjeta®
- Phesgo™
- Pluvicto™ †
- Polivy™
- Poteligeo™
- Provenge®
- Riabni™
- Rituxan® †
- Rituxan Hycela™
- Rybrevant™
- Rylaze™
- Sarclisa®
- Talvey™
- Taclantis*
- Tecvayli™
- Tivdak™
- trastuzumab duocarmazine*
- Trodelvy™
- Vegzelma® §
- Xofigo® †
- Yervoy™
- Zepzelca™
- Zevalin® † §
- zolbetuximab*
- Zynlonta™

Anti PD-1/PD-L1 human monoclonal antibodies**

- camrelizumab*
- cosibelimab*
- balstilimab*
- Bavencio®
- Imfinzi™
- Jemperli
- Keytruda™
- Libtayo®
- Loqtorzi®
- Opdivo®
- penpulimab*
- Tecentriq™
- Tevimbra®
- Zynyz®

Bone-modifying agents

- Evenity®
- Jubbonti®
- Prolia®
- Wyost®
- Xgeva®

Botulinum toxin agents

- Botox®

Chemotherapy-induced nausea and vomiting (CINV) agents

Chimeric antigen receptor (CAR-T) therapies**

- Abecma™
- Breyanzi®
- Carvykti™
- Kymriah™
- obecabtagene autotemcel*
- Tecartus™
- Yescarta™

Endocrine/metabolic agents

- Acthar H.P.®
- cosyntropin depot*
- Lutathera® †
- Sandostatin® LAR
- Somatuline® depot

Enzyme replacement agents**

- Aldurazyme®
- apadamtase alfa/cinaxadamtase alfa*
- Brineura™
- Cerezyme®
- cipaglucosidase alfa*
- Elaprase®
- Eleyso®
- Elfabrio®
- Fabrazyme®
- Kanuma®
- Lamzed®
- Lumizyme®

- Mepsevii™
- Naglazyme®
- Nexviazyme®
- Revcovi™
- Vimizim™
- VPRIV®
- Xenpozyme®

Gene replacement/gene editing therapies**

- Elevidys
- eladocogene exuparvovec*
- exagamglogene autotemcel*
- fidanacogee elaparvovec*
- Hemgenix®
- Lenmeldy™
- Luxturna™
- Lyfgenia™
- marnetegrage autotemcel*
- Roctavian®
- Skysona™
- Vyjuvek®
- Zolgensma®
- Zynteglo®

Hemophilia/Coagulation factors**

Hyaluronate acid products

- Durolane®
- Euflexxa™
- Gel-One®
- Gelsyn-3™
- GenVisc 850®
- Hyalgan®
- Hymovis®
- Supartz®
- Synjoynt™
- Trilonon™
- TriVisc™
- VISCO-3®

Immunological agents

- Actemra[®] IV
- Avsola[™]
- Benlysta[®] IV
- Cosentyx[®]
- Entyvio[™]
- Ilumya[™]
- Inflectra[™]
- Infliximab (unbranded)
- Ixifi[™]
- Omvoh[™]
- Orenia[®] IV
- Remicade[®] ‡
- Renflexis[™]
- Saphnelo[™]
- Simponi[®] Aria
- Skyrizi[®] IV
- Spevigo[®]
- Stelara[®]
- Tofidence[™]
- Tyenne[®]
- Wezlana[™]

Intravenous immune globulin/subcutaneous immune globulin (IVIG/SCIG)**

Myasthenia gravis agents**

- Rystiggo[®]
- Vyvgart[®]
- Vyvgart[®] Hytrulo

Multiple sclerosis agents**

- Briumvi[™]
- Lemtrada[®]
- Ocrevus[™]
- Tyruko
- Tysabri[®]

Neutropenia agents

- efbemalenograstim alfa*
- Fulphila[™]
- Fylnetra[™]
- Lapelga* ‡
- Neupogen[®]
- plinabulin*
- Releuko[™]
- Rolvedon[™]
- Stimufend[®]
- Udenyca[™]
- Ziextenzo[®]

Ophthalmic agents

- abicipar*
- Beovu[®]
- bevacizumab-vikg*
- Bmab-100*
- Byooviz[™]
- Cimerli[™]
- Eylea[®] ‡
- Eylea HD
- Lucentis[®] ‡
- Susvimo[™]
- Tepezza[™]
- Vabysmo[®]

Pulmonary arterial hypertension agents**

- Flolan[®]
- Remodulin[®]
- Revatio[®]
- Trevyent*
- Tyvaso[®]
- Upravi IV
- Veletri[®]
- Ventavis[®]

Respiratory agents

- Cinqair[®]
- Synagis[®]
- Xolair[®]

Respiratory enzymes (Alpha-1 antitrypsin)**

- Aralast
- Glassia[™]
- Prolastin[®]
- Zemaira[®]

Tumor-infiltrating lymphocyte (TIL) and T-cell therapies

- afamitresgene autoleucel*
- Amtagvi[™]
- linvoseltamab*
- tarlamatab*

Miscellaneous therapeutic agents

- Adakveo[®]
- Amvuttra[™]
- Cosela[®]
- Crystvita[®]
- Enjaymo[™]
- Evkeeza[™]
- Gamifant[®]
- Givlaari[®]
- Ilaris[®]
- imetelstat*
- Krystexxa[®]
- Leqvio[®]
- narsoplimab*
- Onpattro[™]
- Oxlumo[®]
- pozelimab*
- Reblozyl[®]
- Rethymic[™]
- Soliris[®] ‡
- Spinraza[™]
- Tzield[™]
- Ultomiris[™]
- Uplizna[™]
- Vyepti[™]
- Xiaflex[®]

* Pending FDA approval.

** All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.

† Precertification review for this drug is provided by CareCore National, LLC d/b/a eviCore healthcare.

‡ Precertification requirements apply to all FDA-approved biosimilars to this reference product.

§ Except for ophthalmological conditions.

This is not a complete list of drugs covered by our plan. For a complete listing, please call the AmeriHealth Member Help Team at **1-866-569-5190 (TTY/TDD: 711)** or visit **amerihealthmedicare.com**.

Limitations, copayments, and restrictions may apply. Benefits, premium, and/or copayments/coinsurance may change on January 1 of each year.

AmeriHealth offers PPO Medicare Advantage plans with a Medicare contract. Enrollment in AmeriHealth PPO Medicare Advantage plans depends on contract renewal.

AmeriHealth Medicare coverage issued by AmeriHealth Insurance Company of New Jersey.